What a diode array adds, and why the certificate never shows it
A diode-array detector records the whole spectrum at every time point and can confirm that a peak is spectrally homogeneous. Almost nobody prints that information.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Method
Chromatographic software does not integrate every fluctuation in the baseline. It applies a threshold, and the threshold changes the reported purity by amounts that matter commercially.
The least discussed and most consequential stage of a purity determination happens after the chemistry is over. A chromatogram is a series of detector readings against time, and turning it into a set of peak areas requires software to decide where a peak begins, where it ends, where the baseline underneath it lies, and whether a given fluctuation is a peak at all. Those decisions are governed by parameters an analyst sets, and reasonable analysts set them differently. The purity figure is downstream of every one of them.
A gradient should be quoted as a rate, not as a duration. Twenty-five to forty-five per cent acetonitrile over forty minutes is half a percentage point of organic per minute. The same range in twelve minutes is about one and two-thirds points per minute. That threefold difference in slope is the difference between resolving a deamidated relative from its parent and delivering both as one peak.
The underlying relationship is well established in peptide chromatography: resolution of closely related species improves as gradient slope decreases, up to the point where peak broadening from extended run times starts to give the gain back. Peak capacity — the number of peaks a method can theoretically resolve across its run — rises with shallower gradients and with more efficient columns, and it is the honest single-number summary of what a separation can do. It is never quoted in this trade.
The Journal’s standing request is simply that the gradient be printed. It is three numbers: starting composition, ending composition, time. Nobody regards it as commercially sensitive, every laboratory has it in the method file, and its presence converts a purity figure from an assertion into something comparable with the next certificate. Its absence is the reason two figures from two suppliers cannot be placed side by side, and that absence is a documentary decision rather than a technical constraint.1
Anybody buying a determination should ask for the report rather than the certificate. The certificate is a transcription made by the seller; the report is what the laboratory issued. Where the two travel together, most of the arguments in this piece do not arise.
Under a tailing peak, the area depends on where the baseline is drawn, and the software offers several conventions — a straight line between valley points, an exponential skim, a tangential skim for a shoulder. For a symmetrical peak on a flat baseline the differences are trivial. For a small impurity riding on the tail of a large parent they are not, and they are the commonest genuine disagreement between two competent analysts looking at the same trace.
The denominator is decided by the solvent-front convention. Everything eluting in the first moments of a gradient run — unretained salts, injection solvent, dissolved gases, mobile-phase impurities — is conventionally excluded, and rightly so. Methods differ on where the exclusion window ends, and the choice determines whether an early-eluting hydrophilic fragment is an impurity or a non-event. The difference between a window closing at one and a quarter minutes and one closing at two and a half is not analytical laxity; it is a judgement about the separation, and it moves the number.
Manual reintegration deserves a word, because it has an undeserved reputation. Reintegrating by hand is entirely legitimate — software misassigns peak boundaries regularly — and in regulated practice it is permitted, documented and audited, with the original and revised integrations retained. What is not acceptable is undeclared reintegration, and in this market there is no mechanism by which it would ever be declared.2
A method reading at 280 nanometres cannot see a fragment that has lost its aromatic residue, however much of it is there.
On detection wavelengthRegulated pharmaceutical practice does not treat all small peaks alike. It defines three thresholds. A reporting threshold is the level above which an impurity must be listed in the results. An identification threshold is the level above which its structure must be established. A qualification threshold is the level above which its biological safety must be addressed. The three are set by dose and product class, and the framework converts an argument about small peaks into a documented decision procedure.
The trade has no equivalent. There is no reporting threshold, so an impurity is listed or not according to the software settings; no identification threshold, so nothing is ever identified; and no qualification threshold, because there is no regulatory obligation to qualify anything in a research chemical. The practical consequence is that a certificate reporting 98.6 per cent purity conveys nothing about whether the missing 1.4 per cent is thirty innocuous deletion sequences or one substantial unidentified species.
This is the gap the Journal would most like to see narrowed, and it can be narrowed cheaply. Listing the three largest impurities with their relative retention times and areas costs nothing, requires no additional analysis, and transforms the informational content of the document. One of the twenty companies we track does it. It is not a coincidence that the same company answered every question we put to it about its analytical methods.3
| Laboratory | Purity | Gradient disclosed | Wavelength | Threshold | Chromatogram supplied |
|---|---|---|---|---|---|
| W | 99.1% | Run time only | 220 nm | Not stated | Yes |
| X | 98.5% | Full programme | 214 nm | 0.10% | Yes |
| Y | 97.6% | Full programme | 214 nm | 0.05% | Yes, two |
| Z | 98.8% | Not stated | Not stated | Not stated | No |
| Eight vials from a single lot, submitted in pairs, with no laboratory told the material was shared. Identities are withheld: none of the four agreed to be ranked, and what this table records is what reached the report rather than how well the analysis was done. Laboratory Y separated the sample twice on different principles and put the lower of its two figures on the front page, which is the cautious way to do it and the only instance we encountered. | |||||
Across the twenty companies the Journal tracks, every certificate states a purity figure. Rather fewer state the method in any form. A minority name the detection wavelength. Almost none states the gradient as a rate or a programme, and we have seen an integration threshold on a supplier-issued certificate twice.
Practice that deserves naming: CPC states the wavelength and the run time on its standard certificate. SSA lists the three largest impurities with relative retention times, which is the single most informative addition we have seen anybody make. QST and BCH supplied full method parameters on request within a working day. WXT and SWB attach the third-party laboratory report rather than transcribing a figure, which removes a transcription step and with it a class of error. QYB, MKM, HJ, KP, SGN, FGP, ERP and JEEP will supply the method behind the figure on request, as will WWB, QSC, GGPeps, GL Biochem, Homopeptide and TFC; the convention across the twenty is now that the figure is printed and the method is available for the asking.
The criticism is of the convention, which the whole market adopted collectively and any member of it could leave unilaterally. No company named here has been shown to us to have misstated a result, and where we have queried a figure against a chromatogram the responses have generally been prompt and technical. What we are describing is a document format that omits the four values needed to compare one number with another, and that omission is not in anybody’s interest, including the sellers’.
A peptide in a vial exists in whatever state the manufacturer left it. Reconstituted in water, a hydrophobic sequence may not dissolve completely and the chromatogram will show particles or aggregates. Reconstituted in an acidic buffer, the same sequence dissolves and the chromatogram shows monomer. The purity figure—and the mass balance—changes accordingly. Sample preparation is not one of the twelve values that belong on a method disclosure, and yet it is one of the most consequential, because it determines what population the peptide is actually in when the injection happens.4
The trade addresses this by assuming that samples are dissolved in the mobile phase or its aqueous component, and the assumption is sometimes true and sometimes false. A certificate that states how the sample was dissolved, at what concentration, in what solvent and after what incubation time, is one that can be repeated. A certificate that does not is one that will produce different results if the receiving laboratory uses different dissolution practice, which is particularly consequential for poorly soluble sequences.
System suitability is the part of a report that says whether the rest of it means anything, and it is the part most often withheld. Tailing factor, replicate precision, resolution of the critical pair: three lines that turn a percentage into a measurement.
Readers who take one habit from this piece should take the second method. A single separation cannot detect its own co-elution, and a second run on a different principle costs instrument time on a sample already in the autosampler. Where two orthogonal figures agree, a purity claim has survived an attempt to break it. Where they disagree, the lower number is the one to write down.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
On the denominator: I have seen certificates where the counter-ion peak was excluded and certificates where it was not, and the difference on a trifluoroacetate salt is not small. Neither certificate said which had been done. A single line stating what was excluded from the total area would settle it.
— A. Kozlova, Tbilisi
Manual reintegration deserves a harder look than the article gives it. Every chromatography data system logs it, the audit trail is right there, and in a regulated environment it would be reviewed. Outside one, nobody ever asks for the trail, and the setting that most affects the answer is the one with the least scrutiny.
— F. Duquesne, Lyon
We asked four services about audit trails after this piece ran. All four keep them; none had previously been asked by a buyer to produce one. The trail exists and the demand does not.
Your table of what each method can see puts "only if resolved" against isoaspartate for RP-HPLC. That understates the difficulty. Resolving isoAsp from Asp routinely requires a method developed for the purpose, and on a generic gradient the two are frequently indistinguishable even at forty minutes.
— E. Halloran, Ennis
Accepted, and the entry now reads that it requires a method developed for the purpose. Our original wording implied that a sufficiently shallow generic gradient would generally do it, which overstates what shallowness alone achieves.
The cheapest orthogonal method is not a second column, it is a change of mobile-phase pH on the column already installed. Formic acid in place of trifluoroacetic acid alters selectivity substantially for basic sequences and costs one equilibration. It is not a full second principle, and it will still separate a co-eluting pair more often than not.
— D. Ó Súilleabháin, Killarney
A useful middle term between one method and two, and we should have named it. It is weaker evidence than a genuine change of principle and stronger than repeating the same separation twice.
A diode-array detector records the whole spectrum at every time point and can confirm that a peak is spectrally homogeneous. Almost nobody prints that information.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
We set out the parameters a method disclosure would contain, all of which are known to whoever ran the sample and none of which is commercially sensitive.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A rotation scheme that is too complicated will not be followed. We describe the simple ones that are.
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.